- Home
- FENC vs ACIU Comparison
FENC vs ACIU Comparison
Compare FENC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- ACIU
- Stock Information
- Founded
- FENC 1996
- ACIU 2003
- Country
- FENC United States
- ACIU Switzerland
- Employees
- FENC N/A
- ACIU N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- ACIU Health Care
- Exchange
- FENC Nasdaq
- ACIU Nasdaq
- Market Cap
- FENC 222.9M
- ACIU 189.1M
- IPO Year
- FENC 2001
- ACIU 2016
- Fundamental
- Price
- FENC $8.63
- ACIU $2.43
- Analyst Decision
- FENC Strong Buy
- ACIU Strong Buy
- Analyst Count
- FENC 2
- ACIU 1
- Target Price
- FENC $13.00
- ACIU $12.00
- AVG Volume (30 Days)
- FENC 68.5K
- ACIU 152.3K
- Earning Date
- FENC 08-12-2025
- ACIU 08-05-2025
- Dividend Yield
- FENC N/A
- ACIU N/A
- EPS Growth
- FENC N/A
- ACIU N/A
- EPS
- FENC N/A
- ACIU N/A
- Revenue
- FENC $30,912,000.00
- ACIU $32,014,254.00
- Revenue This Year
- FENC $0.85
- ACIU N/A
- Revenue Next Year
- FENC $55.16
- ACIU $533.21
- P/E Ratio
- FENC N/A
- ACIU N/A
- Revenue Growth
- FENC N/A
- ACIU 91.20
- 52 Week Low
- FENC $3.96
- ACIU $1.43
- 52 Week High
- FENC $9.30
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- FENC 53.93
- ACIU 73.47
- Support Level
- FENC $8.28
- ACIU $2.02
- Resistance Level
- FENC $8.94
- ACIU $2.15
- Average True Range (ATR)
- FENC 0.36
- ACIU 0.13
- MACD
- FENC -0.05
- ACIU 0.03
- Stochastic Oscillator
- FENC 34.31
- ACIU 83.64
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.